D&D Pharmatech said it adjusted the conversion price of its 2nd convertible bonds from KRW 77,736 to KRW 54,416 due to a decline in the share price, according to a disclosure on October 30, 2026.

D&D Pharmatech disclosed the conversion price adjustment for its 2nd convertible bonds in a filing on October 30, 2026. The company said the conversion price is reset every 6 months based on the share price, and that the adjustment was made because the arithmetic average price of KRW 41,559 was lower than the pre-adjustment conversion price of 77,736 won. According to the company's disclosure, the calculated value fell short of KRW 54,416, which is 70% of the conversion price at issuance, so the floor price of KRW 54,416 was applied as the new conversion price, and the number of shares available for conversion increased as a result.

1. 01

   The reason for the adjustment is the conversion price adjustment due to a decline in the share price, and the adjusted price applies from October 30, 2026.

2. 02

   After the adjustment, the number of shares available for conversion increased from 2,913,691 shares before the adjustment to 4,162,353 shares.

3. 03

   According to the company's disclosure, the new conversion price of KRW 54,416 was applied as the floor price, which equals 70% of the conversion price at issuance.

4. 04

   The company said it will not hold a separate board meeting because the conversion price adjustment resulted from a decline in the share price.

An AI model translated the Korean summary of this filing into English; every number is carried over from the Korean original. Reference information, not investment advice.

Key figures

Conversion price before adjustment

KRW 77,736

Conversion price after adjustment

KRW 54,416

Shares available for conversion before adjustment

2,913,691 shares

Shares available for conversion after adjustment

4,162,353 shares

Total face value of unconverted bonds (electronic registration)

KRW 226.5 billion

Arithmetic average price

KRW 41,559

Filing facts

Filing type

Conversion or Exercise Price Adjustment

Report name

Adjustment of Conversion Price (Series 2)

Filed

Oct 30, 2026

Receipt number

20261030901174